New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:28 EDTBCRXBioCryst price target raised to $24 from $21 at H.C. Wainwright
H.C. Wainwright raised its price target for BioCryst shares to $24 saying two overhangs have been removed with the positive Phase 2a data for oral kallikrein inhibitor 4161 and the recent equity financing. The firm reiterates a Buy rating on the stock.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
09:56 EDTBCRXBioCryst management to meet with JPMorgan
Meetings to be held in Boston on January 29-30 hosted by JPMorgan.
09:19 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:59 EDTBCRXBioCryst grants fast track designation for BCX4161
BioCryst announced that the FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. BioCryst is enrolling HAE patients in the OPuS-2 trial of BCX4161; a double-blind, randomized, placebo controlled trial conducted in the U.S. and certain EU countries, with the goal of demonstrating the efficacy and safety of BCX4161 treatment for 12 weeks in approximately 100 patients with HAE. BioCryst expects to report results from OPuS-2 by the end of 2015.
January 25, 2015
13:57 EDTBCRXUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 14, 2015
09:16 EDTBCRXOn The Fly: Pre-market Movers
HIGHER: ZIOPHARM (ZIOP), up 53% after the company and Intrexon (XON) announced a licensing agreement with University of Texas. Intrexon shares are also up 12%... GameStop (GME), up 10.6% after reporting holiday SSS, providing guidance for the fourth quarter and fiscal 2014, and being upgraded at Pacific Crest... Smith Micro (SMSI), up 12.7% after reporting preliminary fourth quarter revenue and providing revenue guidance for the first quarter and fiscal 2015... BioCryst (BCRX), up 3.2% after receiving a positive opinion on EMA orphan drug designation for BCX4161... GoPro (GPRO), up 1% following analyst remarks that sell-off after yesterday's report on Apple (AAPL) patent was "overdone." DOWN AFTER EARNINGS: JPMorgan (JPM), down 2.7%... Wells Fargo (WFC), down 2.2%... Banking peers down as well, with Bank of America (BAC) down 2.8% and Citi (C) down 2%. ALSO LOWER: Tesla (TSLA), down 9% following comments made by CEO Elon Musk at an automotive conference in Detroit regarding a slowdown in China... New Media (NEWM), down 4.8% after 7M share spot secondary priced at $21.70... General Motors (GM), down 3% after giving 2015 guidance, saying it is on track to meet previously announced 2016 financial targets... Apple (AAPL), down 1% following lawsuit against Ericsson (ERIC) and countersuit filing.
07:16 EDTBCRXBioCryst receives positive opinion on EMA orphan drug designation for BCX4161
Subscribe for More Information
January 12, 2015
11:14 EDTBCRXDenver patient being tested for Ebola, KUSA-TV reports
A patient recently returned from Ebola affected areas in Africa is being tested in Denver for the disease, reported local NBC affiliate 9New KUSA-TV. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE) and Alpha Pro Tech (APT). Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use